



Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 16 December 2019.

I am pleased to confirm the following.

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?

Abemaciclib + aromatase inhibitor * Abemaciclib + Fulvestrant Alpelisib + Fulvestrant Atezolizumab **Bevacizumab** Eribulin Everolimus + Exemestane Fulvestrant as a single agent Gemcitabine + paclitaxel Lapatinib Neratinib Olaparib Palbociclib + aromatase inhibitor* Pertuzumab + trastuzumab + docetaxel Ribociclib + aromatase inhibitor* Ribociclib + Fulvestrant Talazoparib Herceptin SC Herceptin IV Transtuzumab biosimilar SC Transtuzumab biosimilar IV Trastuzumab emtansine Other active systemic anti-cancer therapy ** *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for 2a Neo-adjuvant breast cancer; Transtuzumab total SC Transtuzumab total IV 2.b Adjuvant breast cancer;

> As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns.

Transtuzumab total SC Transtuzumab total IV 3. In the past 3 months, how many Urothelial cancer patients were treated with; Atezolizumab Carboplatinum in combination with another agent Carboplatinum single agent Cisplatinum in combination with another agent Cisplatinum single agent Nivolumab Pembrolizumab Any other chemo regimen without cisplatinum or carboplatinum Other active systemic anti-cancer therapy [please state] Palliative care only

Please see attached.

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.